Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Intellia Therapeutics (NTLA) Change in Receivables (2016 - 2025)

Intellia Therapeutics (NTLA) has disclosed Change in Receivables for 10 consecutive years, with -$1.6 million as the latest value for Q4 2025.

  • Quarterly Change in Receivables fell 369.44% to -$1.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $951000.0 through Dec 2025, up 103.4% year-over-year, with the annual reading at $951000.0 for FY2025, 103.4% up from the prior year.
  • Change in Receivables for Q4 2025 was -$1.6 million at Intellia Therapeutics, down from -$303000.0 in the prior quarter.
  • The five-year high for Change in Receivables was $30.0 million in Q4 2023, with the low at -$24.1 million in Q2 2024.
  • Average Change in Receivables over 5 years is $366900.0, with a median of $61000.0 recorded in 2023.
  • The sharpest move saw Change in Receivables surged 11850.98% in 2023, then crashed 16059.6% in 2024.
  • Over 5 years, Change in Receivables stood at -$460000.0 in 2021, then surged by 44.57% to -$255000.0 in 2022, then soared by 11850.98% to $30.0 million in 2023, then plummeted by 101.12% to -$337000.0 in 2024, then tumbled by 369.44% to -$1.6 million in 2025.
  • According to Business Quant data, Change in Receivables over the past three periods came in at -$1.6 million, -$303000.0, and $849000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.